What is the half-life of ACE-031?

ACE-031 has a half-life of Unknown, which is why it's typically administered As needed for optimal therapeutic effect.

How do I reconstitute ACE-031?

Add bacteriostatic water to the peptide vial slowly down the side. Typical reconstitution uses 2-3ml of water for a 5mg vial. Gently swirl, do not shake.

What is the half-life of ACE-031?

ACE-031 has a half-life of Unknown, which is why it's typically administered As needed for optimal therapeutic effect.

How do I reconstitute ACE-031?

Add bacteriostatic water to the peptide vial slowly down the side. Typical reconstitution uses 2-3ml of water for a 5mg vial. Gently swirl, do not shake.

Healing & Recovery

Phase 2

ACE-031

Also known as: ActRIIB-Fc, ACE031, ACVR2B-Fc

Overview

Key Facts

Primary Goal: Research and therapeutic applications of ACE-031

Acts as a soluble decoy receptor for myostatin, activin A/B, GDF-11, and BMP-9/10. Prevents ligand binding to membrane-bound ActRIIB, blocking Smad2/3 signaling.

Dosing Information

Half-Life

10-15 days (Fc fusion extends half-life)

Typical Dose

0.5–3 mg

Frequency

Once every 2 weeks (based on clinical trial dosing)

Cycle Length

8-12 weeks (limited to research context)

Administration Routes:

subcutaneousintravenous

Benefits

Significant increases in lean muscle mass observed in clinical trials
Reduction in fat mass independent of exercise
Broad inhibition of multiple negative regulators of muscle growth
Potential bone mineral density improvement
Dose-dependent muscle volume increases shown in healthy volunteers

Side Effects

Epistaxis (nosebleeds) and gum bleeding due to effects on vascular remodelinguncommonmild

Telangiectasias (dilated blood vessels) — led to trial discontinuationuncommonmild

Erythrocytosis (elevated red blood cell count)uncommonmild

Minor injection site reactionsuncommonmild

Potential suppression of reproductive hormonesuncommonmild

Mechanism of Action

Acts as a soluble decoy receptor for myostatin, activin A/B, GDF-11, and BMP-9/10

Prevents ligand binding to membrane-bound ActRIIB, blocking Smad2/3 signaling

Removes multiple parallel inhibitory pathways that limit muscle growth

Off-target BMP-9/10 inhibition affects vascular endothelial signaling (responsible for side effects)

Contraindications

Do not use this peptide if any of the following apply:

Any bleeding disorder or anticoagulant therapy
History of hereditary hemorrhagic telangiectasia (HHT)
Cardiovascular disease or vascular abnormalities
Pregnancy or breastfeeding
Active malignancy

Storage & Reconstitution

Unreconstituted (Powder)

Temperature2–8°C (36–46°F) or -20°C (-4°F) for long-term

DurationUp to 3 months

Reconstituted (Mixed)

Temperature2–8°C (36–46°F)

Duration2-4 weeks

Research Summary

Phase 2

A Phase II trial in boys with Duchenne muscular dystrophy (NCT01099761) showed dose-dependent increases in lean body mass and bone mineral density. However, the trial was discontinued due to epistaxis and telangiectasias attributed to off-target inhibition of BMP-9/10. Subsequent research by Acceleron led to more selective agents (luspatercept) that avoid the vascular side effects. ACE-031 remains a proof of concept for the ActRIIB pathway in muscle growth.

Frequently Asked Questions

Common questions about ACE-031

UK-Specific Information

Exclusive data points and guidance for UK residents using ACE-031

UK Lab Testing

Recommended labs: Medichecks, Thriva (£89-£149 for peptide safety panel)

Generate a trackable link to share this peptide information on TikTok